Parecoxib Improves the Outcomes of Acute Mild and Moderate Pancreatitis

Objectives The aim of this study was to evaluate the role of parecoxib in patients with different severities of acute pancreatitis (AP). Methods A total of 772 eligible patients with AP were divided into 4 groups: mild and moderately AP (MAP) treated with parecoxib (group A, n = 236), MAP without parecoxib treatment (group B, n = 453), severe AP (SAP) treated with parecoxib (group C, n = 28), and SAP without parecoxib treatment (group D, n = 55). Patients in group A were exactly matched with patients in group B by propensity score matching, similar to the matching between group C and group D. Results The morbidity of abdominal infection in group A was significantly lower as compared with that in group B ( P < 0.050). The progression of MAP to SAP significantly decreased in group A than group B ( P < 0.050). No significant differences were observed between group C and group D. The risk factors independently related to the progression of MAP included alcoholic/high-fat dietary ( P = 0.028) and parecoxib administration ( P = 0.011). Conclusions Early administration of parecoxib could reduce the morbidity of complications among patients with MAP. Parecoxib may prevent the progression of MAP to SAP and improve its outcomes.